First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn
KEYNOTE-B10 (KN-B10) is a single‑arm, phase‑IV trial exploring carboplatin, paclitaxel, and pembrolizumab (CPP) as first‑line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
The trial shows that CPP provides antitumor activity similar to the standard platinum/5‑FU/pembrolizumab regimen while potentially offering a more manageable safety profile, providing a therapeutic alternative for patients whose disease is platinum‑sensitive or naïve.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability